TD Cowen analyst Ritu Baral maintains $Neurogene (NGNE.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 45.4% and a total average return of 11.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
The stock of Neurogene is currently trading 'near cash' following disclosures about a Serious Adverse Event in its NGN-401 high dose trial and the termination of its Battens program. Despite these setbacks, management anticipates no clinical hold after their discussions with the FDA, noting the safety of lower doses.
The firm updated its projections for 3Q24 earnings and adjusted its expectations after learning that a trial participant of NGN-401 was in critical condition following administration of the high dose. Furthermore, the anticipated market share of NGN-401 in the Rett syndrome gene therapy market has been adjusted to 50%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
